Rylaze

Chemical Nameasparaginase erwinia chrysanthemi (recombinant)-rywn
Dosage FormInjection (intramuscular; 10 mg/0.5 mL)
Drug ClassEnzymes
SystemBlood
CompanyJazz Pharmaceuticals
Approval Year2021

Indication

  • For the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli-derived asparaginase
Last updated on 3/15/2022

More on this drug: Clinical Trials

Document TitleYearSource
Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) Prescribing Information.2021Jazz Pharmaceuticals Inc., Palo Alto, CA

Have we missed a study, or would you like to comment on a study?